Scarica l'app Stockscreener
9.2374
0.44%
0.0474
Precedente Chiudi:
$9.19
Aprire:
$9.19
Volume 24 ore:
51,897
Relative Volume:
0.35
Capitalizzazione di mercato:
$2.79B
Reddito:
$391.87M
Utile/perdita netta:
$-441.45M
Rapporto P/E:
-4.9932
EPS:
-1.85
Flusso di cassa netto:
$-301.21M
1 W Prestazione:
-10.91%
1M Prestazione:
-16.85%
6M Prestazione:
-24.96%
1 anno Prestazione:
-21.04%
Intervallo 1D:
$9.19
$9.30
Intervallo di 1 settimana:
$9.15
$10.25
Portata 52W:
$9.15
$14.76
Alvotech Stock (ALVO) Company Profile
Confronta ALVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
9.22 | 2.79B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
161.34 | 73.88B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.18 | 48.17B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.48 | 47.59B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.31 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Iniziato | UBS | Buy |
| 2024-01-29 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-09-21 | Iniziato | Barclays | Equal Weight |
| 2022-09-07 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Downgrade | Citigroup | Buy → Sell |
| 2022-07-26 | Iniziato | Citigroup | Buy |
Mostra tutto
Alvotech Borsa (ALVO) Ultime notizie
The Escalator: HHS, Spectrum Science, Alvotech and more - Medical Marketing and Media
Oaktree Capital Management LP Sells 606,322 Shares of Alvotech (NASDAQ:ALVO) - MarketBeat
Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs - insights.citeline.com
Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year - Center for Biosimilars®
Alvotech (NASDAQ:ALVO) Issues Earnings Results - MarketBeat
Alvotech (NASDAQ:ALVO) Stock Price Down 7.6%Time to Sell? - MarketBeat
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge By Investing.com - Investing.com Australia
Aurion names Arnaud Lacoste CEO - BioCentury
Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024 - insights.citeline.com
Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Alvotech Achieves Record Revenue Growth in 2024 - TipRanks
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge - Investing.com India
Trump Must Be ‘Harsh’ With Big Pharma, Says Icelandic Drugmaker - Bloomberg.com
Alvotech Appoints Dr. Balaji V. Prasad As Chief Strategy Officer - MarketScreener
Alvotech Appoints New Chief Strategy Officer to Strengthen Market Position - TipRanks
Alvotech Achieves Record 2024 Financial Results and Expands Biosimilar Pipeline - TipRanks
Iceland's Alvotech Appoints Chief Strategy Officer - MarketScreener
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - The Manila Times
Alvotech earnings missed by $0.04, revenue topped estimates - Investing.com Australia
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech earnings missed by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
Alvotech : Press Release Full Year 2024 - MarketScreener
Alvotech Reports Record Results for 2024 and Provides Business Update - The Manila Times
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com
Alvotech And Advanz Make First Omalizumab Filing - Citeline News & Insights
Alvotech SA MHRA Accepts Marketing Application For AVT23 Biosimilar To Xolair - Marketscreener.com
Alvotech’s Biosimilar to Xolair Gains UK Regulatory Acceptance - TipRanks
Alvotech , Kashiv Biosciences LLC and Advanz Pharma Announces UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair - MarketScreener
UK Medicines and Healthcare Products Regulatory - GlobeNewswire
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - The Manila Times
Earnings Scheduled For March 26, 2025 - Benzinga
UK Medicines and Healthcare Products Regulatory Agency - GlobeNewswire
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewswire Inc.
Royce & Associates LP Raises Stock Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech, Partners Say UK Regulator Accepted Market Application for Proposed Xolair Biosimilar - Marketscreener.com
FDA accepts Teva, Alvotech BLAs for Simponi biosimilars - MSN
Alvotech (ALVO) Expected to Announce Earnings on Wednesday - MarketBeat
Short Interest in Alvotech (NASDAQ:ALVO) Expands By 21.7% - MarketBeat
Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003 - MSN
FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars - Drug Store News
Northland reiterates Alvotech stock with $28 target on acquisition By Investing.com - Investing.com Canada
Alvotech Acquires Xbrane's R&D Operations, Expanding Biosimilars Development Capabilities - Nasdaq
Northland reiterates Alvotech stock with $28 target on acquisition - Investing.com India
Icelandic Biotech Company Alvotech to Explore Listing in Stockholm - MarketWatch
Alvotech Azioni (ALVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
7.85%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):